Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jarno Drost

Showing results (31-40 of 88) with videos related to

Pageof 9
Sort By:
International Journal of Molecular Sciences|September 9, 2023
CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in <i>KMT2A</i>-Rearranged Acute Lymphoblastic LeukemiaPauline Schneider, Priscilla Wander, Susan T C J M Arentsen-Peters, et al.
Molecular Cell|January 1, 2013
eRNAs are required for p53-dependent enhancer activity and gene transcriptionCarlos A Melo, Jarno Drost, Patrick J Wijchers, et al.
Cell Reports. Medicine|December 21, 2024
Metabolic profiling of patient-derived organoids reveals nucleotide synthesis as a metabolic vulnerability in malignant rhabdoid tumorsMarjolein M G Kes, Francisco Morales-Rodriguez, Esther A Zaal, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2017
Genetic dissection of colorectal cancer progression by orthotopic transplantation of engineered cancer organoidsArianna Fumagalli, Jarno Drost, Saskia J E Suijkerbuijk, et al.
Science (New York, N.Y.)|September 16, 2017
Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancerJarno Drost, Ruben van Boxtel, Francis Blokzijl, et al.
Communications Biology|November 1, 2022
Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRAS<sup>G12D</sup> glycolytic colorectal tumorsMarlies C Ludikhuize, Sira Gevers, Nguyen T B Nguyen, et al.
Critical Reviews in Oncology/Hematology|May 7, 2020
Paediatric metanephric tumours: a clinicopathological and molecular characterisationDominique V C de Jel, Janna A Hol, Ariadne H A G Ooms, et al.
European Journal of Cancer (Oxford, England : 1990)|December 20, 2020
Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials - A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meetingJesper Brok, Annelies M C Mavinkurve-Groothuis, Jarno Drost, et al.
Cell|September 10, 2014
Identification of multipotent luminal progenitor cells in human prostate organoid culturesWouter R Karthaus, Phillip J Iaquinta, Jarno Drost, et al.
Cancers|July 2, 2021
Prognostic Factors for Wilms Tumor Recurrence: A Review of the LiteratureAlissa Groenendijk, Filippo Spreafico, Ronald R de Krijger, et al.
Pageof 9

Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
International Journal of Molecular Sciences|September 9, 2023
CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in <i>KMT2A</i>-Rearranged Acute Lymphoblastic LeukemiaPauline Schneider, Priscilla Wander, Susan T C J M Arentsen-Peters, et al.
Molecular Cell|January 1, 2013
eRNAs are required for p53-dependent enhancer activity and gene transcriptionCarlos A Melo, Jarno Drost, Patrick J Wijchers, et al.
Cell Reports. Medicine|December 21, 2024
Metabolic profiling of patient-derived organoids reveals nucleotide synthesis as a metabolic vulnerability in malignant rhabdoid tumorsMarjolein M G Kes, Francisco Morales-Rodriguez, Esther A Zaal, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2017
Genetic dissection of colorectal cancer progression by orthotopic transplantation of engineered cancer organoidsArianna Fumagalli, Jarno Drost, Saskia J E Suijkerbuijk, et al.
Science (New York, N.Y.)|September 16, 2017
Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancerJarno Drost, Ruben van Boxtel, Francis Blokzijl, et al.
Communications Biology|November 1, 2022
Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRAS<sup>G12D</sup> glycolytic colorectal tumorsMarlies C Ludikhuize, Sira Gevers, Nguyen T B Nguyen, et al.
Critical Reviews in Oncology/Hematology|May 7, 2020
Paediatric metanephric tumours: a clinicopathological and molecular characterisationDominique V C de Jel, Janna A Hol, Ariadne H A G Ooms, et al.
European Journal of Cancer (Oxford, England : 1990)|December 20, 2020
Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials - A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meetingJesper Brok, Annelies M C Mavinkurve-Groothuis, Jarno Drost, et al.
Cell|September 10, 2014
Identification of multipotent luminal progenitor cells in human prostate organoid culturesWouter R Karthaus, Phillip J Iaquinta, Jarno Drost, et al.
Cancers|July 2, 2021
Prognostic Factors for Wilms Tumor Recurrence: A Review of the LiteratureAlissa Groenendijk, Filippo Spreafico, Ronald R de Krijger, et al.
Pageof 9